Journal of Carcinogenesis & Mutagenesis

Daliborka Bursac

Publications

• Case Report
  Patient with Primary T790M Mutation in Lung Adenocarcinoma Treated with Gefitinib as a First-Line and Osimertinib as a Second-Line Therapy: A Case Report
  Author(s): Daliborka Bursac, Tatjana Sarcev, Danica SazdanicVelikic, Nevena Djukic, Vanesa Sekurus, Svetlana Petkov and Goran StojanovicDaliborka Bursac, Tatjana Sarcev, Danica SazdanicVelikic, Nevena Djukic, Vanesa Sekurus, Svetlana Petkov and Goran Stojanovic
  
  The identification of Epidermal Growth Factor Receptor (EGFR) mutations represents a major milestone in the treatment of advanced non-small-cell lung cancer. The activating mutations of EGFR occur in 10%-15% NSCLC Caucasian and 30%-40% East Asian patients, approximately. The EGFR T790M mutation is present in approximately 50%-60% of resistant cases as a secondary mutation, but as a primary less than 1%. Treatment with thyrosine kinase inhibitors (TKIs) is more efficient with fewer side effects compared with classic treatment modalities. We reported a rare case lung adenocarcinoma patient with primary T790M mutation treated with gefitinib as a fist line and osimertinib as a second line therapy. .. View More»
  

  Abstract PDF